Centessa Pharmaceuticals appoints Mario Alberto Accardi PhD as CEO and member of the Board, succeeding Saurabh Saha MD PhD, effective January 1, 2026.
The transition signifies Centessa's shift to a pure-play orexin portfolio, emphasizing orexin therapeutics in neuroscience indications.
Dr. Accardi's deep understanding of orexin biology positions Centessa for advancements in neurological, neurodegenerative, and neuropsychiatric disorders.
Strategic Evolution
Transition from diversified R&D start-up to orexin-focused organization for neurology advancements.
Focus on Orexin Pipeline
Concentration on OX2R agonists for neurological disorders with plans for clinical programs in 2026.
Leadership Acknowledgment
Recognition of Saurabh Saha's contributions in building Centessa's foundation and orexin franchise.
Potential Growth Opportunities
Belief in orexin therapeutics' potential and positioning Centessa for growth in neuroscience.
- Advancement of OX2R agonists offering growth potential in neuroscience.
- Focus on orexin franchise with clinical programs and strategic milestones in 2026.
The CEO transition at Centessa Pharmaceuticals marks a strategic shift towards orexin-focused advancements in neuroscience, setting the stage for significant developments in 2026 and beyond.